Items Tagged ‘Stages I-IIIA Lung Cancer – Non-Small Cell’

October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


October 25th, 2016

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status

By

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer […]

View full entry

Tags: 2016, atezolizumab, BTD, ESMO, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, PD-L1, Recurrent Lung Cancer - Non-Small Cell


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab


October 19th, 2015

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer

By

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is divided into two main groups based upon the type of cells comprising the cancer: non-squamous and squamous cell. […]

View full entry

Tags: FDA approval, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, non-squamous, nsclc, opdivo, Stages I-IIIA Lung Cancer - Non-Small Cell


December 6th, 2014

Xalkori™ (crizotinib) Targeted Therapy More Effective Than Chemotherapy for Treatment of Lung Cancer

By

A new drug Xalkori™ (crizotinib) is more beneficial than chemotherapy for certain individuals with lung cancer according to new research published in the New England Journal of Medicine. Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of developing effective new approaches to treatment. Ninety percent […]

View full entry

Tags: alk, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, xalkori


December 5th, 2014

Recent Treatment Advancements in Lung Cancer

By

By Christina S. Baik, MD, MPH Assistant Professor, University of Washington School of Medicine Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center Facing a lung cancer diagnosis? It is important to know the details of the disease and what treatment options are available. Make sure you understand the specific cancer, its stage, and its […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Recurrent Lung Cancer - Non-Small Cell, sclc, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


December 3rd, 2014

5 Things Women Should Know about Lung Cancer

By

By Christina S. Baik, MD, MPH Assistant Professor, University of Washington School of Medicine Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center 1. Smoking causes the deadliest form of cancer. Lung cancer is the second most common cancer among women (after breast cancer), but it takes almost twice as many lives, making it […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Recurrent Lung Cancer - Non-Small Cell, sclc, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


June 12th, 2013

Standard Dose of Radiation Therapy Outperforms Higher Dose for Advanced Non-Small Cell Lung Cancer

By

In a phase III clinical trial, a standard dose of radiation therapy was more effective than a higher dose for the treatment of stage III non-small cell lung cancer (NSCLC). These results will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology. Radiation therapy plays an important role in the treatment […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


November 9th, 2012

Stereotactic Body Radiation Improves Lung Cancer Survival

By

Stereotactic body radiation for early-stage, inoperable non-small cell lung cancer yields high overall survival rates and low toxicity compared to conventional radiotherapy, according to the results of a study presented at the annual meeting of the American Society for Radiation Oncology in Boston, Massachusetts. In fact, the approach doubled overall survival rates historically achieved with […]

View full entry

Tags: Lung Cancer - Non-Small Cell, News, Stages I-IIIA Lung Cancer - Non-Small Cell


September 19th, 2012

Genetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer

By

Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study published in Nature. The discovery could lead to new targeted agents designed to treat this type of cancer. Lung cancer remains the leading cause of […]

View full entry

Tags: Lung Cancer - Non-Small Cell, News, Recurrent Lung Cancer - Non-Small Cell, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


May 14th, 2012

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

By

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer death in the United States. Non–small cell lung cancer (NSCLC) […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


March 2nd, 2012

Some Lung Cancer Patients Receive Potentially Unhelpful Treatment

By

Among older patients who undergo surgery for locally advanced, non-small-cell lung cancer, many receive postoperative radiation therapy. The radiation therapy, however, may not improve treatment outcomes. These results were published in Cancer. Lung cancer remains the leading cause of cancer death in theUnited States. Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, Stages I-IIIA Lung Cancer - Non-Small Cell


October 13th, 2011

Higher Radiation Dose Does Not Benefit Lung Cancer Patients

By

Among patients with Stage III non-small cell lung cancer, treatment with a higher dose of radiation therapy does not result in better overall survival than a standard dose of radiation therapy. These results were presented at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO). Lung cancer remains the leading cause of […]

View full entry

Tags: Lung Cancer - Non-Small Cell, News, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


August 25th, 2011

Elderly, Minorities and Women Under-represented in Lung Cancer Clinical Trials

By

Compared with the demographics of lung cancer in the United States, the elderly, minorities, and women remain vastly under-represented in lung cancer clinical trials. These results were presented at the 14th World Conference on Lung Cancer. Clinical trials are the process through which medications ultimately become approved by the Food and Drug Administration (FDA) in […]

View full entry

Tags: Lung Cancer - Non-Small Cell, News, Recurrent Lung Cancer - Non-Small Cell, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


August 17th, 2011

Genetic Assay Predicts Survival in Early Non-small Cell Lung Cancer

By

A genetic test performed on a sample of tumor tissue helps predict survival among patients with early, non-squamous, non-small cell lung cancer (NSCLC) who are treated with surgery only. Patients with low predicted survival may benefit from the addition of chemotherapy. These results were recently presented at the 14th World Conference on Lung Cancer meeting […]

View full entry

Tags: Lung Cancer - Non-Small Cell, News, Stages I-IIIA Lung Cancer - Non-Small Cell